Kubota Pharmaceutical Holdings FY2017 Analyst Meeting
February 21, 2018
Kubota Pharmaceutical Holdings is committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Cautionary Statement Regarding Forward Looking Statements
This presentation contains forward-looking statements concerning our product development, our ability to successfully commercialize our product candidates, our technology, our competitors, our intellectual property, our financial condition and operating results and our plans for research and development programs and the timing thereof that involve risks, uncertainties and assumptions. Such forward-looking statements typically can be identified by the use of words such as “expect,”
“estimate,” “anticipate,” “forecast,” “intend,” “project,” “target,” “plan,” “believe” and similar terms and expressions. These statements are based on the current estimates and assumptions of the management of Kubota Pharmaceutical Holdings Co., Ltd. as of the date of this presentation and are subject to uncertainty and risks in circumstances, including, but not limited to the risk that our product candidates will not demonstrate the expected benefits and will not achieve regulatory approval or be successfully commercialized, the risk of delays in our ongoing or expected clinical trials, the risk that new developments in the intensely competitive ophthalmic pharmaceutical and device markets require changes in our clinical trial plans or limit the potential benefits of our product candidates, the accuracy of our estimates of the size and characteristics of the markets that may be addressed by our product candidates, the risk that our pre-clinical development efforts may not yield additional product candidates, and other risks and uncertainties inherent in the process of discovering and developing therapeutics and devices that demonstrate safety and efficacy. Given these uncertainties, you should not place undue reliance upon these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties, assumptions and other factors that may cause our actual results to be materially different from those reflected in such forward-looking statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, those set forth in our reports on file with the Tokyo Securities Exchange and the United States Securities and Exchange Commission. The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. All statements contained in this presentation are made only as of the date of this presentation.
“Acucela,” the Acucela logo and “Kubota” are among the registered trademarks or trademarks of Kubota Pharmaceutical Holdings in various jurisdictions.
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 2 Company Overview and Development Strategy Kubota Pharmaceutical Group Vision
Our goal is to preserve and restore vision for millions of people suffering from eye diseases worldwide.
▪ Address unmet medical needs in sight-threatening diseases through scientific innovations
▪ Build a unique company offering continuous value creation to our society
▪ Create an positive working environment and enhance quality of life for employees
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 4 Company Overview
An Ophthalmology-Focused, Science-Driven Company
People and Strategy Business Development • Executive leadership with experience in • Quick Win – Fast Fail health care management, life science • Translational Research –Initiate pre- administration & technology clinical and clinical studies, and obtain • Broad-skilled employee base in R&D and proof of concept (POC) in human operations with broad industry relationships
Internal Research Partnership • Continue to expand ophthalmic product • Partner with leading universities and pipeline through internal research and seek research institutes for collaboration and in- for in-licensing opportunities licensing in the U.S. and Europe • Establish a total solution in ophthalmology • Enhance our technologies by partnering for drugs and devices with large pharmaceutical companies in or outside of Japan
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 5 Leading Causes of Blindness in Japan, US and Europe
• 33 million people blind worldwide, and 191 million people suffer from moderate and severe vision impairment (MSVI)
Japan1 Unites States2 Europe3
Others Glaucoma Other AMD 34% 21% 25% 26% Others 45% DR DR 5% AMD 16% 54% Glaucoma Glaucoma 6% 20% 8% 10% 12% Retinochoroidal Cataract DR Retinitis Atrophy AMD 9% 9% Pigmentosa
Source: 1) 厚生労働省 難治性疾患等克服研究事業「網膜脈絡膜・視神経萎縮症に関する調査研究 平成25(2013)年度」報告書 (A 2013 Report by Ministry of Health, Labour and Welfare) 2) Nathan C. et al. Causes and Prevalence of Visual Impairment Among Adults in the United States. Arch Ophthalmol122 (2004) 3) Kocur I, Resnikoff S. Visual Impairment and blindness in Europe and their prevention. British Journal of Ophthalmology 86, 716-722 (2002)
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 6 Retinal Diseases and IOL: Global Market Revenue Forecast
Global revenue forecast to reach $17.5B in 2020 CAGR 6.7% from 2017 – 2020 17,472 16,570 15,545 4,358 14,375 4,092 3,864 3,651 2,570 2,520 2,453 1,285 2,359 1,036 818 429
6,676 6,767 6,220 6,424
1,716 1,986 2,246 2,492
2017 2018 2019 2020 DR Wet AMD Dry AMD Other Retinal Dieases IOL Sources： Visiongain, Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025。 （US$ in millions） Market Scope, 2015 Comprehensive Report on the Global IOL Market。
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 7 Business Development Focus
• Kubota Pharma’s business focus is to bridge the chasm between early discovery and late confirmatory stages, namely, the translational research stage. − Partner with universities and leverage public funding in the discovery phase − Build best in class exploratory development capabilities in house − Build U.S.-centric confirmatory / commercialization capabilities and partner ex-U.S.
Kubota Pharma’s $65B $30B Focus Area annual spend mainly from large annual spend in the pharmaceutical companies U.S. mainly from universities and large pharmaceutical $5B companies annual spend
Nonclinical Exploratory Lead optimization / Confirmatory Commercialization Target Discovery Lead Identification Development Development preclinical profiling Development & LCM (GxP) (POC)
Discovery Translational Research Confirmatory
Internal Research / Partnerships In House In House / Partnered
Source: Give to Cure 2015
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 8 Development Pipeline
Therapeutics Program Indications Pre-clinical Phase 1 Phase 2 Phase 3
Emixustat HCI Proliferative Diabetic Retinopathy
Emixustat HCI Stargardt Disease
Small Molecule Cataract, Presbyopia
Gene Therapy Retinitis Pigmentosa
Diabetic Macular Edema, Small Molecule Wet AMD
Devices Design & Clinical Trial & Regulatory Program Description Prototype Product Eng. Approval [510(k)]
Remote Medical Home-based miniature OCT Monitoring Device (optical coherence tomography)
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 9 Diabetic Retinopathy using Emixustat Hydrochloride Manifestations and Treatment of Diabetic Retinopathy A leading cause of vision impairment and blindness in working-age adults globally, ~105 million people affected worldwide
Nonproliferative DR Proliferative DR
Diabetic macular edema
Retinal hemorrhages New vessels Neovascularization surrounded by hard Generally no exudate treatment Laser, Anti-VEGF, Vitrectomy Current Treatments • All procedures invasive • Risk of sight-threatening side-effects Cotton Hard exudates in fovea wool spots • Increased burden on patients Anti-VEGF, Corticosteroids, Vitrectomy
Source: Stitt AW et al. Advances in our understanding of diabetic retinopathy. Clinical Science (2013) 125, 1–17. Abbreviations: DR, diabetic retinopathy; VEGF, vascular endothelial growth factor
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 11 Emixustat: a Potential Paradigm Shift in the Treatment of Diabetic Retinopathy
全く新しいアプローチTotally new approach to Oral administration diabetic retinopathy Potential to transform 網膜には光を電気信号に変え current therapeutic る働きをする「視覚サイクThe visual cycle is the biological conversion of light into an electrical landscape of invasive ル」と呼ばれる仕組みがあるsignal in the retina. treatment modalities
網膜は暗い環境では視覚サイThe retina has a higher metabolic rate クルによる代謝が高く、よりin the dark than in light, using more energy and oxygen. 多くのエネルギーと酸素を消 To benefit more patients 費するEmixustat is designed to modulate visual cycle activity and reduce the • Initial focus on PDR, the エミクススタトは視覚サイクmetabolic burden of the eye. This most serious form of DR includes reducing the retina's oxygen • Evaluate potential in slowing NPDR ルを調節する働きがあるのdemand, which may slow the progression to PDR で、網膜の代謝と酸素需要をprogression of diabetic retinopathy. and also DME 軽減し、血管新生を抑制する ことが期待される Abbreviations: DME, diabetic macular edema; DR, diabetic retinopathy; NPDR, nonproliferative diabetic retinopathy; PDR, proli ferative diabetic retinopathy
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 12 Phase 2 Study of Emixustat for Proliferative Diabetic Retinopathy (PDR) Complete
2016 2017 2018 2019
Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
Phase 2
• Multicenter (up to 6 clinical sites in the US) randomized, double-blinded, placebo- controlled trial
• 18 patients with PDR took emixustat (5 mg to 40 mg titration) or placebo orally once daily for 12 weeks
• Evaluations − Change in biomarkers of diabetic retinopathy disease − Effects on retinal hemorrhage, neovascularization, and vision • Results − Numerical differences favoring emixustat over placebo in the change-from-baseline biomarker of vascular endothelial growth factor (VEGF)
2018 Data analysis to determine development strategy
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 13 Forecast for the Global Diabetic Retinopathy(1) Market
CAGR 13.3%
2,492 2,246 1,986 1,716
2017 2018 2019 2020
Source： Visiongain, Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025。 （US$ in millions） 1) Including Proliferative diabetic retinopathy and diabetic macular edema
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 14 Stargardt Disease using Emixustat Hydrochloride Stargardt Disease: a Genetic Disorder
Stargardt disease is a genetically inherited disorder of the retina • Stargardt is a serious unmet medical need, with fewer than 150,000 people estimated to be patients in the U.S., Japan and Europe, combined.
• Mutations in a gene called ABCA4 are the most common cause of Stargardt disease.
• There are many symptoms a person with Stargardt may experience including spots in the vision, color vision deficits, distortion, blurriness, and loss of central vision in both eyes.
• Kubota Pharma receives Orphan Drug Designation from the FDA for the treatment of Stargardt disease in January 2017 Source: National Eye Institute. https://nei.nih.gov/health/stargardt/star_facts. Retrieved July 2, 2016
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 16 Stargardt Disease: Disease Progression and Proposed Emixustat Mechanism of Action
Defective gene: ABCA4
Accumulation of lipofuscin (lipid, proteins, vitamin A toxins) leading to free radical production and activation of complement system Emixustat Blocks the accumulation of RPE Dysfunction lipofuscin and vitamin A toxins
Death of RPE
Photoreceptor Cell Death
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 17 Attenuation of A2E Accumulation in abca4-/-Mice Treated 3 Months with Emixustat
Reduction of Lipofuscin Reduction of A2E Accumulation
Day 0 Day 90
30
25
wild-type 20 * * 15
* A2E A2E (pmole/eye) abca4-/- 10 (vehicle)
5
T0 Vehicle 0.03 0.1 0.3 1.0 3.0 abca4-/- Emixustat (mg/kg) (Emixustat 3mg/kg) *p ˂ 0.05
Modified From: Bavik C, Henry SH, Zhang Y, Mitts K, McGinn T, Budzynski E, et al. (2015) Visual Cycle Modulation as an Approach toward Preservation of Retinal Integrity. PLoS ONE 10(5): e0124940. doi:10.1371/journal.pone.0124940
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 18 Phase 2a Study of Emixustat for Stargardt Disease Complete; Moving to Phase 3
2017 2018 2019
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Phase ２a > Phase ３ FPFV target • Multicenter (up to 6 clinical sites in the US), randomized, double-blind trial • 22 patients diagnosed with macular atrophy secondary to Stargardt randomly assigned to one of three treatment arms in a 1:1:1 ratio. Treatment arms include: emixustat 2.5 mg, 5 mg, and 10 mg. Subjects orally took study drug once daily in the evening for one month. Designed to evaluate the pharmacodynamics, safety and tolerability of emixustat in subjects. • Evaluations − Change in electrical response of the retina to a flash of light, as measured by electroretinogram − Percent suppression compared to baseline of rod b-wave amplitude recovery after a photobleaching light • Results − ERG recovery after photobleaching was dose-dependent and a maximum reduction in recovery rate was more than 90% compared to baseline − Showed safety and tolerability of emixustat with the administered doses in subjects 2018 Planned initiation of phase 3 clinical trial
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 19 Cataracts and Presbyopia using Small Molecule Compound Protein Aggregation in Crystalline Lens of the Eye Leads to Cataract
Impact on Vision
Highly ordered proteins
Clear Vision
Denatured proteins
Low protein order / protein aggregation Cloudy Vision
Denatured proteins aggregate and obstruct light, causing cloudy vision
Source: Zhao L, Chen XJ, Zhu J, et al. Lanosterol reverses protein aggregation in cataracts. Nature 523 (7562). 607-611 (2015) National Eye Institute. https://nei.nih.gov/health/cataract/cataract_facts. Retrieved July 2, 2016
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 21 Small Molecule Compound: A New Treatment Potential
Currently, there is no non-surgical treatment available for cataracts 1. Multiple incisions are made to access the lens 2. High-frequency ultrasound breaks up the lens into small pieces, then removed with suction (phacoemulsification) 3. A clear intraocular lens is inserted in the same location the natural lens occupied 4. The incisions are closed and a protective shield is placed over the eye (in some procedures)
Lanosterol-related small molecule compound • Non-invasive, pharmacological treatment • Dissolves protein aggregates and establishes order • Naturally occurring compound in the human body • Has the potential to reverse lens opacification
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 22 Small Molecule Compound: Development Plan
Targeted for Cataract and Presbyopia
2016-2018 Pre-clinical development necessary to file an IND
Formulation development
Phase 1/2 clinical study planned for patients with 2018 cataract Assess lens opacity in humans; evaluation of near vision
2018 POC (Proof of Concept) Target
Abbreviation: IND, investigational new drug
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 23 Forecast for the Global IOL Market
CAGR 6.1%
4,358 4,092 3,864 3,651
2017 2018 2019 2020
Source： （US$ in millions） Market Scope, 2015 Comprehensive Report on the Global IOL Market
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 24 Retinitis Pigmentosa using Gene Therapy (Optogenetics) Retinitis Pigmentosa is a Blinding Disease
• Affects roughly 1 in 4,000 people, both in the United States and worldwide (NEI)1 • Approximately 1.5 million people worldwide are affected by the disease 2 • Earliest and most frequent symptom is night blindness, decreased vision or tunnel vision 3 • Progressive loss of vision in childhood leads generally to blindness by age 40 4 • The cause of RP is complex, with over 100 different gene mutations identified 5
NORMAL VISION DECREASED VISION TUNNEL VISION BLINDNESS Source: 1) Genetics Home Reference, Retinitis Pigmentosa. https://ghr.nlm.nih.gov/condition/retinitis-pigmentosa. Retrieved Nov 7, 2016 2) Vaidya P, Vaidaya A. Retinitis Pigmentosa: Disease Encumbrance in the Eurozone. Int J Ophthalmol Clin Res. 2:030 (2015) 3) MedilinePlus, Retinitis Pigmentosa. https://medlineplus.gov/ency/article/001029.htm. Retrieved Nov 7, 2016 4) American Academy of Ophthalmology. Retinitis Pigmentosa Causes. http://www.aao.org/eye-health/diseases/retinitis-pigmentosa-cause, Retrieved July 2, 2016 5) National Human Genome Research Institute. Leaning About Retinitis Pigmentosa. https://www.genome.gov/13514348/. Retrieved Nov 7, 2016 Abbreviations: NEI, National Eye Institute; RP, retinitis pigmentosa
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 26 Optogenetics: Gene Therapy Technology
Technology allows expression of human rhodopsin in ON bipolar cells using a viral vector
• Rhodopsin’s biological mechanism imparts a relatively high level of light sensitivity for this type of therapy and as a human protein, may minimize any immunological impact
• Genetic mutation-independent therapy DEAD PHOTORECEPTORS
HUMAN RHODOPSIN
Light Sensitive ON Bipolar Cells
Source: Buchen L. Illuminating the brain. Nature 465. 26–28 (2010)
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 27 Optogenetics Development Plan
Kubota Pharma intends to pursue Orphan Drug status to allow for potentially rapid development and extended regulatory exclusivity.
2016-2018 Pre-clinical development necessary to file an IND
Anticipated initiation of Phase 2 clinical study for 2018-2019 patients with Retinitis Pigmentosa
2019 POC (Proof of Concept) Target
Abbreviation: IND, investigational new drug
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 28 DME and wet AMD using Biomimetic Technology-based Small Molecule Compound Inflammation is a Hallmark in Multiple Sight-Threatening Ocular Diseases Posterior Segment Anterior Segment • Allergy • AMD • Dry Eye • Geographic Atrophy • Retinal Vein Occlusion • Diabetic Retinopathy Reduce burden on patients by either • Uveitis intravitreal or oral Panocular • Post-surgical inflammation administration Allergy Dry Eye Uveitis Geographic AMD Post-surgical Atrophy Retinal Vein Occlusion inflammation Diabetic Retinopathy Drug Anti- Steroids Steroids None Anti-VEGF Classes histamines Immunosuppressant Immunosuppressant
Drug Patanol® Restasis® Durezol® Eylea® Name Xiidra® Lucentis® Avastin® *All registered trademarks are the property of their respective owners.
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 30 Biomimetic Technology-based Small Molecule Compound
Potential small molecule pharmacologic treatment for retinal neovascular disease
• The proprietary technology modulates endogenous factors released during the inflammatory process at the early pathogenic stages of diabetic macular edema (DME), wet age-related macular degeneration (wet AMD) and other retinal neovascular conditions. − Demonstrated the ability to inhibit vascular endothelial growth factor (VEGF) induced vascular leakage comparable to anti-VEGF therapy, and without loss of native microvasculature − Vessels appeared to be better preserved than with the anti-VEGF treatment suggesting less occlusion • Evaluate the potential of these proprietary molecules to be dosed less frequently and exert therapeutic effects over a longer period of time than current anti-VEGF biologic drugs used as standard of care. − Potential of this novel therapeutic approach to provide better outcomes and an improved delivery paradigm, administered either intravitreally or orally, for patients suffering from a variety of retinal neovascular diseases
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 31 Biomimetic Technology-based Small Molecule Compound: Development Plan
Targeted for diabetic macular edema (DME) and wet AMD
2018 - 2019 Pre-clinical development for IND filing
2019-2020 Initiation of Phase 2 clinical study targeted
2020 - 2021 POC (Proof of Concept) Target
Abbreviation: IND, investigational new drug
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 32 Forecast for the Global Wet AMD Market
CAGR 2.9%
6,676 6,767 6,220 6,424
2017 2018 2019 2020
Source： （US$ in millions） Visiongain, Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 33 Remote Medical Monitoring Device Home-based Miniature OCT (optical coherence tomography) Miniature OCT Solution: PBOS Low cost, home-based, ophthalmic self-monitoring OCT device (optical coherence tomography)
• Small handheld OCT device for self monitoring by patients • Real-time monitoring of eye disease therapy progression • Addresses increase in demand for mobile Health applications (mHealth) in home care and remote medical care field
In its first iteration, the PBOS aims to improve treatment outcome in patients diagnosed and treated for DME, wet AMD, and other neovascular retinal diseases.
The PBOS is being designed to detect nascent disease progression and support patient re-treatment prior to irreversible vision loss due to disease progression.
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 35 PBOS System Overview
OCT Device: Patient Self-Check ① Internet ② Mobile App: “Cloud” Patient Raw data analysis Self-Monitoring ③ Physician / Healthcare Institution Access
Using the internet, PBOS is a low-cost home-based patient self-monitoring device, designed to monitor disease progression to support effective treatment regimen.
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 36 PBOS Development Plan
Targeted for wet AMD, DME, and other neovascular retinal disease
2017-2018 Design and prototype
2018 Clinical trial and product engineering targeted
2019 Anticipated regulatory approval, 510(k)
Abbreviation: IND, investigational new drug
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 37 FY2017 Financial Results Overview of FY2017: P/L (IFRS)
Year ended December 31, ￥ Millions Inc/Dec Reasons for change 2016 2017 Operating 846 ― -846 Termination of our collaboration with Otsuka revenue
Expenses 4,917 3,620 -1,297
R&D 2,335 2,380 ＋44 Emixustat clinical programs for Stargardt disease Internal research 1,354 2,380 ＋1,026 and proliferative diabetic retinopathy and new product development such as PBOS etc. Collaborative Completion of Phase 2b/3 clinical trial for dry AMD 981 ― -981 research in May ’16 • Corporate legal expenses and charges related to the Redomicile Transaction：¥ -442 • Stock compensation: ¥ -382 G&A 2,582 1,240 -1,342 • Salary, stock compensation, benefits, taxes and severance costs for officer positions eliminated in Q2-2016 resulted in 2017 expense reduction of ¥ -307 etc. Loss from -4,071 -3,620 ＋451 operations Net loss -3,911 -3,445 ＋466
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 39 Overview of FY2017: B/S (IFRS)
￥ Millions Dec 31, 2016 Dec 31, 2017 Inc/Dec Reasons for change
Current assets 14,839 11,673 -3,166 Cash and cash equivalents, and Other 14,256 11,197 -3,059 (*) financial assets Decrease due to collection of trade Other 583 476 -107 receivable Non-current assets 2,333 1,724 -610 Other financial assets 2,218 1,566 -652 (*) Other 115 158 ＋43 Total assets 17,172 13,396 -3,776 Decrease in Accrued expense due Current liabilities 537 327 -211 to completion of Phase 2b/3 for dry AMD and Redomicile transaction. Non-current liabilities 111 103 -8 Net loss and Cumulative translation Equity 16,524 12,967 -3,557 adjustment Liabilities and Equity 17,172 13,396 -3,776
(*) Total Cash and cash Decrease primarily due to cash used equivalents, and Other 16,474 12,763 -3,711 in R&D activities and G&A cost financial assets
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 40 Financial Outlook for FY2018*
￥ Millions Operating Loss from Loss before Net loss revenue operation income tax FY2018 (Forecast) － -3,500 -3,370 -3,370 FY2017 (Actual) － -3,620 -3,445 -3,445 Exchange rate for the forecast: 1 US Dollar = \110 Outlook for Operating revenue
➢ We are pursuing various partnering efforts and expects to generate revenue in the future through collaboration with strategic partners. Outlook for Loss from operations ➢ R&D cost will increase due to Phase 3 for Stargardt and continued development of PBOS and our other programs.
➢ However, Loss from operation will decrease due to decreased of G&A cost such as Compensation and Overhead cost.
* Forward-looking financial information and estimates contained in this presentation were previously disclosed by the Company in the Company’s Kessan Tanshin dated February 13, 2018. Such forward-looking financial information and estimates speak only as of the dates of initial disclosure and this presentation is neither updating nor confirming the previously provided forward-looking financial information, guidance and estimates.
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 41 Appendix Board of Directors
Directors Background
Ryo Kubota, MD PhD Chairman, President and Chief Executive Officer and also founder of Acucela Inc.
Chief Financial Officer — DeNA Co., Ltd. Shintaro Asako Previously: Chief Financial Officer — MediciNova, Inc.
President and Chief Executive Officer — M’s Science Corporation Shiro Mita, PhD Previously: Executive Director of Drug Discovery, Director — Santen Pharmaceuticals Co., Ltd
Corporate Auditor — Koinobori Associates Inc. Eisaku Nakamura Previously: Director and General Manager — Bio Sight Capital Co., Ltd , Chief Executive Officer and President — Berevno Corporation, Board of Directors — CanBas Corporation and Activus Pharma Co. Ltd.
President — RT Consulting, Inc. Robert Takeuchi Previously: President — SOFTBANK Finance, America Corporation, Director of International Equity Sales — Credit Suisse First Boston, Board of Directors SBI Investment Co., Ltd. and Quark Pharmaceuticals, Inc.
Kubota Pharmaceutical Holdings Co., Ltd. [4596] 43 Kubota Pharmaceutical Holdings is committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide.